Skip to main content
Premium Trial:

Request an Annual Quote

BGI to Use Agilent Enrichment and QC Products, Liquid Handling Platform in Sequencing Workflow

Premium

This story was originally published April 14.

Agilent Technologies said last week that large-scale Chinese genome center BGI will use several of its products as part of its next-generation sequencing process.

Specifically, BGI will use Agilent's SureSelect solution-based target enrichment product for targeted sequencing in human genetic studies, particularly in cancer genome projects.
BGI researchers worked with Agilent's China Life Science group and Agilent R&D to test and validate SureSelect.

In addition, BGI is adopting Agilent's Bravo automated liquid-handling platform for next-generation sequencing sample preparation, and the company's 2100 Bioanalyzer to analyze DNA libraries prior to sequencing.

According to its website, BGI currently has 28 Illumina Genome Analyzers, 10 Illumina HiSeq 2000, and two Applied Biosystems SOLiD systems installed. Earlier this year, BGI ordered 128 Illumina HiSeq 2000 sequencers, which are expected to be delivered by the end of this year.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.